Evgen Pharma (LON:EVG)‘s stock had its “buy” rating restated by analysts at Northland Securities in a research report issued on Tuesday, September 11th.
Separately, Northland Capital Partners reissued a “buy” rating and set a GBX 113 ($1.47) price objective on shares of Evgen Pharma in a research note on Friday, July 27th.
Shares of LON EVG remained flat at $GBX 17.25 ($0.22) during midday trading on Tuesday. 22,495 shares of the company traded hands, compared to its average volume of 207,445. Evgen Pharma has a one year low of GBX 12.15 ($0.16) and a one year high of GBX 29.25 ($0.38).
Evgen Pharma Company Profile
Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex for synthesizing and stabilizing the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer.
Further Reading: Discover Your Risk Tolerance
Receive News & Ratings for Evgen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evgen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.